Their results indicated three key points: (a) MSI-H revealed a better survival impact, even for the BRAF-mutated CRC; (b) both KRAS- and BRAF-mutated CRC had a poor survival impact, but the prognostic impact of KRAS was weaker than that of BRAF; (c) CIMP status could be representative of the BRAF mutation or MSI-H in consideration of the prognostic impact. This evidence concerns the gene BRAF and colorectal carcinoma.